XTX Topco Ltd Invests $268,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

XTX Topco Ltd purchased a new stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 142,493 shares of the company’s stock, valued at approximately $268,000. XTX Topco Ltd owned 0.46% of Actinium Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ATNM. Interchange Capital Partners LLC bought a new position in shares of Actinium Pharmaceuticals in the third quarter valued at approximately $37,000. The Manufacturers Life Insurance Company purchased a new position in Actinium Pharmaceuticals during the 2nd quarter worth $92,000. Wellington Management Group LLP bought a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter worth $112,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 183.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock valued at $120,000 after purchasing an additional 41,250 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Actinium Pharmaceuticals during the second quarter valued at about $142,000. Institutional investors own 27.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Stephens reiterated an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. Finally, StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Price Performance

NYSE ATNM opened at $1.16 on Thursday. The company’s fifty day moving average price is $1.58. The company has a market cap of $36.19 million, a PE ratio of -0.83 and a beta of 0.07. Actinium Pharmaceuticals, Inc. has a 1-year low of $1.16 and a 1-year high of $10.24.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).